Isoginkgetin derivative IP2 enhances the adaptive immune response against tumor antigens

The success of cancer immunotherapy relies on the induction of an immunoprotective response targeting tumor antigens (TAs) presented on MHC-I molecules. We demonstrated that the splicing inhibitor isoginkgetin and its water-soluble and non-toxic derivative IP2 act at the production stage of the pion...

Descripción completa

Detalles Bibliográficos
Autores principales: Darrigrand, Romain, Pierson, Alison, Rouillon, Marine, Renko, Dolor, Boulpicante, Mathilde, Bouyssié, David, Mouton-Barbosa, Emmanuelle, Marcoux, Julien, Garcia, Camille, Ghosh, Michael, Alami, Mouad, Apcher, Sébastien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921396/
https://www.ncbi.nlm.nih.gov/pubmed/33649389
http://dx.doi.org/10.1038/s42003-021-01801-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921396/
https://www.ncbi.nlm.nih.gov/pubmed/33649389
http://dx.doi.org/10.1038/s42003-021-01801-2

Ejemplares similares